This site is intended for healthcare professionals only
large study confirms that COVID-19 mRNA vaccines are safe in pregnancy
This new study, from The Canadian National Vaccine Safety (CANVAS) Network, looked at data from participants across seven Canadian provinces and territories between December 2020 and November 2021. All vaccinated participants were asked to self-report any health events during the seven days following each dose of COVID-19 vaccine.
The unvaccinated pregnant control group was asked to record any health problems over the seven days before they filled out the survey. In total, 191,360 women aged 15-49 years with known pregnancy status completed the first dose survey and 94,937 completed the second dose survey.
The researchers found that 4.0% (226/5,597) of mRNA-vaccinated pregnant females reported a significant health event within seven days after dose one of an mRNA vaccine, and 7.3% after dose two. The most common significant health events after dose two in pregnant females were a general feeling of being unwell, headache/migraine, and respiratory tract infection.
In comparison, 3.2% of pregnant unvaccinated participants reported similar events in the seven days prior to survey completion. In the vaccinated non-pregnant control group, 6.3% reported a significant health event in the week after dose one and 11.3% after dose two.
Dr Julie Bettinger et. al, Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study, The Lancet Infectious Diseases, 11-Aug-2022
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at email@example.com.